# Melanotan 2 FAQ — Research Questions Answered from the Published Literature

> Melanotan 2 frequently asked questions answered from the peer-reviewed research record — mechanism, dosage, side effects, pharmacokinetics, and receptor pharmacology. Cited and editorial.

The following questions about Melanotan 2 (MT-II) are answered directly from the published research literature. Every quantitative claim is cited. This is editorial commentary on the science — not medical advice.

## What is Melanotan 2?

Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Developed at the University of Arizona, it was designed to be more potent and metabolically stable than native alpha-MSH. Full sequence: Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2. Binds MC1R, MC3R, MC4R, and MC5R. Studied primarily for melanogenesis stimulation, erectile function, and appetite modulation. [1][18]

## How long does Melanotan 2 take to tan?

In the Dorr 1996 Phase I study, five SC doses over ten days produced measurable reflectance-based pigmentation increases within 2–3 weeks. [1] Individual response varied with baseline Fitzpatrick skin type.

## Does Melanotan 2 affect the kidneys?

A 2020 case report documented right-sided renal infarction affecting ~50% of kidney tissue in a patient after 27 mg of MT-II SC over six months. [4] First published renal infarction case in 215 MT-II exposures recorded at the Swedish Poison Center.

## Does Melanotan 2 lower testosterone?

No peer-reviewed study has demonstrated MT-II lowering testosterone in humans. Raposinho 2003 documented in rats that central MT-II infusion did not affect LH pulsatility. [14]

## Does Melanotan 2 make your hair darker?

MC1R activation can in principle stimulate melanin synthesis in hair follicle melanocytes. Case reports and forum observations mention hair darkening [7]; no controlled human study has been published.

## Does Melanotan cause fat loss?

Cote 2017: 40-day central melanocortin activation in rats reduced intra-abdominal fat by 35–55%, 3-fold BAT thermogenesis elevation. [5] Anorexic tolerance developed within 5 days; thermogenic effect persisted.

## Does Melanotan 2 increase dopamine?

Central melanocortin receptor signaling interacts with dopaminergic and oxytocinergic pathways. Thurston 2022: MC4R agonism enhanced amygdala-insula connectivity in a 31-subject randomized fMRI trial. [11] Paiva 2017: increased oxytocin neuron firing rates following IV MT-II in rats. [15]

## Does Melanotan 2 change eye color?

No peer-reviewed evidence that MT-II changes iris color. Adult iris color change is not a documented outcome in any published MT-II trial or case series.

## What is the Melanotan 2 half life?

Plasma half-life approximately 1 hour based on rat IV pharmacokinetic data (Ugwu 1994). [16] MT-II's cyclic structure confers ~4–6 fold greater metabolic stability than linear alpha-MSH (~10–15 min). Melanogenic effects persist far longer.

## What melanocortin receptors does Melanotan 2 bind?

MT-II binds MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite, autonomic tone), and MC5R (exocrine gland function). MC4R agonism drives the central effects documented in the Wessells [2][3] and Cote [5] studies.

## References

[1] Dorr RT et al. Life Sciences. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H et al. Journal of Urology. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Wessells H et al. International Journal of Impotence Research. 2000;12 Suppl 4:S74-S79. https://pubmed.ncbi.nlm.nih.gov/11035391/
[4] Peters B et al. CEN Case Reports. 2020;9(2):150-153. https://pmc.ncbi.nlm.nih.gov/articles/PMC7148395/
[5] Cote I et al. Canadian Journal of Physiology and Pharmacology. 2017;95(2):206-214. https://pubmed.ncbi.nlm.nih.gov/28051332/
[7] Gilhooley E et al. Dermatology. 2021;237(6):966-975. https://pubmed.ncbi.nlm.nih.gov/34464955/
[11] Thurston L et al. Journal of Clinical Investigation. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[14] Raposinho PD et al. Journal of Neuroendocrinology. 2003;15(2):173-181. https://pubmed.ncbi.nlm.nih.gov/12535159/
[15] Paiva L et al. Journal of Neuroendocrinology. 2017;29(2):e12453. https://pubmed.ncbi.nlm.nih.gov/28009464/
[16] Ugwu SO et al. Biopharmaceutics and Drug Disposition. 1994;15(6):487-499. https://pubmed.ncbi.nlm.nih.gov/7981427/
[18] Hadley ME. Peptides. 2005;26(10):1687-1689. https://pubmed.ncbi.nlm.nih.gov/15996790/

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.